LitAlert ~~

    • Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    • Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN.
    • Lancet Oncol. 2023 Jan 6:S1470-2045(22)00739-2. doi: 10.1016/S1470-2045(22)00739-2. Epub ahead of print.

    •• Identifier: NCT02595905: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases. ( . Accessed 2023 Jan 7.)

    • Breast Cancer Advances in 2022 Showcase a Shifting Landscape.
    • Sparano JA.
    • OncLive. 2023 Jan 6.